Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease

Parkinson’s disease (PD) is a complex neurodegenerative disorder featuring both motor and nonmotor symptoms associated with a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Oxidative stress (OS) has been implicated in the pathogenesis of PD. Genetic and environmental...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yumin Wang, Luyan Gao, Jichao Chen, Qiang Li, Liang Huo, Yanchao Wang, Hongquan Wang, Jichen Du
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	Parkinson’s disease oxidative stress Nrf2 heme oxygenase-1 neuroprotection Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/28f5383c4cc645389fe0e568dd9d7b21
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:28f5383c4cc645389fe0e568dd9d7b21
record_format	dspace
spelling	oai:doaj.org-article:28f5383c4cc645389fe0e568dd9d7b212021-11-30T13:42:47ZPharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease1663-981210.3389/fphar.2021.757161https://doaj.org/article/28f5383c4cc645389fe0e568dd9d7b212021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.757161/fullhttps://doaj.org/toc/1663-9812Parkinson’s disease (PD) is a complex neurodegenerative disorder featuring both motor and nonmotor symptoms associated with a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Oxidative stress (OS) has been implicated in the pathogenesis of PD. Genetic and environmental factors can produce OS, which has been implicated as a core contributor to the initiation and progression of PD through the degeneration of dopaminergic neurons. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) orchestrates activation of multiple protective genes, including heme oxygenase-1 (HO-1), which protects cells from OS. Nrf2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis. Recently, a series of studies have reported that different bioactive compounds were shown to be able to activate Nrf2/antioxidant response element (ARE) and can ameliorate PD-associated neurotoxin, both in animal models and in tissue culture. In this review, we briefly overview the sources of OS and the association between OS and the pathogenesis of PD. Then, we provided a concise overview of Nrf2/ARE pathway and delineated the role played by activation of Nrf2/HO-1 in PD. At last, we expand our discussion to the neuroprotective effects of pharmacological modulation of Nrf2/HO-1 by bioactive compounds and the potential application of Nrf2 activators for the treatment of PD. This review suggests that pharmacological modulation of Nrf2/HO-1 signaling pathway by bioactive compounds is a therapeutic target of PD.Yumin WangLuyan GaoJichao ChenQiang LiLiang HuoYanchao WangHongquan WangJichen DuFrontiers Media S.A.articleParkinson’s diseaseoxidative stressNrf2heme oxygenase-1neuroprotectionTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Parkinson’s disease oxidative stress Nrf2 heme oxygenase-1 neuroprotection Therapeutics. Pharmacology RM1-950
spellingShingle	Parkinson’s disease oxidative stress Nrf2 heme oxygenase-1 neuroprotection Therapeutics. Pharmacology RM1-950 Yumin Wang Luyan Gao Jichao Chen Qiang Li Liang Huo Yanchao Wang Hongquan Wang Jichen Du Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
description	Parkinson’s disease (PD) is a complex neurodegenerative disorder featuring both motor and nonmotor symptoms associated with a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Oxidative stress (OS) has been implicated in the pathogenesis of PD. Genetic and environmental factors can produce OS, which has been implicated as a core contributor to the initiation and progression of PD through the degeneration of dopaminergic neurons. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) orchestrates activation of multiple protective genes, including heme oxygenase-1 (HO-1), which protects cells from OS. Nrf2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis. Recently, a series of studies have reported that different bioactive compounds were shown to be able to activate Nrf2/antioxidant response element (ARE) and can ameliorate PD-associated neurotoxin, both in animal models and in tissue culture. In this review, we briefly overview the sources of OS and the association between OS and the pathogenesis of PD. Then, we provided a concise overview of Nrf2/ARE pathway and delineated the role played by activation of Nrf2/HO-1 in PD. At last, we expand our discussion to the neuroprotective effects of pharmacological modulation of Nrf2/HO-1 by bioactive compounds and the potential application of Nrf2 activators for the treatment of PD. This review suggests that pharmacological modulation of Nrf2/HO-1 signaling pathway by bioactive compounds is a therapeutic target of PD.
format	article
author	Yumin Wang Luyan Gao Jichao Chen Qiang Li Liang Huo Yanchao Wang Hongquan Wang Jichen Du
author_facet	Yumin Wang Luyan Gao Jichao Chen Qiang Li Liang Huo Yanchao Wang Hongquan Wang Jichen Du
author_sort	Yumin Wang
title	Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
title_short	Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
title_full	Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
title_fullStr	Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
title_full_unstemmed	Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
title_sort	pharmacological modulation of nrf2/ho-1 signaling pathway as a therapeutic target of parkinson’s disease
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/28f5383c4cc645389fe0e568dd9d7b21
work_keys_str_mv	AT yuminwang pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease AT luyangao pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease AT jichaochen pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease AT qiangli pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease AT lianghuo pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease AT yanchaowang pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease AT hongquanwang pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease AT jichendu pharmacologicalmodulationofnrf2ho1signalingpathwayasatherapeutictargetofparkinsonsdisease
_version_	1718406552092672000

Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease

Ejemplares similares